Mciver CJ; Bull RA; Tu ET; Rawlinson WD; White PA, 2005, 'Norovirus and Sapovirus', in McIver CJ (ed.), A Compendium of Laboratory Diagnostic Methods for Common and Unusual Enteric Pathogens - an Australian Perspective, edn. 1, Australian Society of Microbiology, Australia, pp. 191 - 198
Matthews GV; Bhagani S; Van der Valk M; Rockstroh J; Feld JJ; Rauch A; Thurnheer C; Bruneau J; Kim A; Hellard M; Shaw D; Gane E; Nelson M; Ingiliz P; Applegate TL; Grebely J; Marks P; Martinello M; Petoumenos K; Dore GJ; Marks P; Amjad S; Tu E; Tamaddoni M; Thurnheer MC; Gilleece Y; Fraser C; Moriggia A; Lutz T; Moon J; Read P; Kim AY; Ustianowski A; Cordes C; Sasadeusz J; Hull M; Braun D, 2021, 'Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection', Journal of Hepatology, vol. 75, pp. 829 - 839, http://dx.doi.org/10.1016/j.jhep.2021.04.056
Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV, 2020, 'Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection', Hepatology, vol. 72, pp. 7 - 18, http://dx.doi.org/10.1002/hep.31003
Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Filep E; Petoumenos K; Marks P; Applegate T; Grebely J; Dore G; Nelson M; Matthews G, 2019, 'Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection', JOURNAL OF HEPATOLOGY, vol. 70, pp. E231 - E231, http://dx.doi.org/10.1016/S0618-8278(19)30432-3
Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, vol. 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S; Fisher M; Rockstroh J; Stellbrink J; Merlin K; Yeung J; Fsadni B; Marks K; Suzuki K; Rismanto N; Salomon H; Rubio AE; Chibo D; Birch C; Swenson L; Chan D; Berg T; Obermeier M; Schuelter E; Aragon SS; Luebke N; Coughlan S; Dean J; Iwatani Y; Teran GR; Avila S; Sirivichayakul S; Naphassanant M; Ubolyam S; Kaye S; Land S; Walker S; Haubrich R; DeJesus E; Berthon-Jones N; Espinosa N; Courtney-Vega K; Absar N; Haskelberg H; Robson R; Donaldson A; Guelman D; Gambardella L; Valdovinos M; Arnaiz J; Beleta H; Ramos N; Targa M; Späth B; Boesecke C; Engelhardt A; Perry N; Beckthold B; Drummond F; Lefevre E; Corr S; Grant C; Lupo S; Peroni L; Sanchez M; De Paz Sierra M; Viloria G; Parlante A; Bissio E; Luchetti P; Confalonieri V; Warley E; Vieni I; Vilas C; Zarate A; Mayer G; Elliot J; Hagenauer M; Kelley M, 2018, 'Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study', HIV Medicine, vol. 19, pp. 65 - 71, http://dx.doi.org/10.1111/hiv.12532
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S, 2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study', Clinical Infectious Diseases, vol. 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207
Tu E; Swenson LC; Land S; Pett S; Emery S; Marks K; Kelleher AD; Kaye S; Kaiser R; Schuelter E; Harrigan R, 2013, 'Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc switch collaborative study', Journal of Clinical Microbiology, vol. 51, pp. 2063 - 2071, http://dx.doi.org/10.1128/JCM.00510-13
Baleriola C; Tu E; Johal H; Gillis J; Ison M; Law MG; Coghlan P; Rawlinson W, 2012, 'Organ donor screening using parallel nucleic acid testing allows assessment of transmission risk and assay results in real time.', Transplant Infectious Disease, vol. 14, pp. 278 - 287, http://dx.doi.org/10.1111/j.1399-3062.2012.00734.x
Nguyen O; Sheppeard V; Douglas MW; Tu E; Rawlinson W, 2010, 'Acute hepatitis C infection with evidence of heterosexual transmission', Journal of Clinical Virology, vol. 49, pp. 65 - 68, http://dx.doi.org/10.1016/j.jcv.2010.06.008
Eden J-S; Bull RA; Tu ET; McIver CJ; Michael JL; John AM; David WS; Jennie M; Rawlinson WD; White PA, 2010, 'Norovirus GII.4 variant 2006b caused epidemics of acute gastroenteritis in Australia during 2007 and 2008', Journal of Clinical Virology, vol. 49, pp. 265 - 271, http://dx.doi.org/10.1016/j.jcv.2010.09.001
Kainer G, 2010, 'Influenze B Virus Transmission in Receipients of Kidney and Lung Transplants From an Infected Donor', Transplantation, vol. 90, pp. 99 - 102, http://dx.doi.org/10.1097/TP.0b013e3181da1933
Tu ET; Bull RA; Kim M; Mciver CJ; Heron LG; Rawlinson WD; White PA, 2008, 'Norovirus excretion in an aged-care setting', Journal of Clinical Microbiology, vol. 46, pp. 2119 - 2121, http://dx.doi.org/10.1128/JCM.02198-07
Tu ET; Bull RA; Greening G; Hewitt JE; Lyon M; Marshall J; Rawlinson WD; White PA, 2008, 'Epidemics of gastroenteritis during 2006 were associated with the spread of norovirus GII.4 variants 2006a and 2006b', Clinical Infectious Diseases, vol. 46, pp. 413 - 420, http://dx.doi.org/10.1086/525259
Tu ET; Nguyen TV; Lee PJ; Bull RA; Musto JA; Hansman G; White PA; Rawlinson WD; Mciver CJ, 2007, 'Norovirus GII.4 strains and outbreaks, Australia', Emerging Infectious Diseases, vol. 13, pp. 1128 - 1130, http://dx.doi.org/10.3201/eid1307.060999
Bull RA; Tu ET; Mciver CJ; Rawlinson WD; White PA, 2006, 'Emergence of a new norovirus genotype II.4 variant associated with global outbreaks of gastroenteritis', Journal of Clinical Microbiology, vol. 44, pp. 327 - 333, http://dx.doi.org/10.1128/JCM.44.2.327-333.2006
Hansman G; Takeda N; Katayama K; Tu ET; Mciver CJ; Rawlinson WD; White PA, 2006, 'Genetic diversity of sapovirus in children, Australia', Emerging Infectious Diseases, vol. 12, pp. 141 - 143, http://dx.doi.org/10.3201/eid1201.050846
Land S; Tu E; Swenson L; Kelleher A; Kaye S; Pett SL; Emery S; Kaiser R; Silk D; Berthon-Jones N; Harrigan PR, 2013, 'Proviral DNA testing of HIV tropism in the Maraviroc Switch Collaborative Study (MARCH) - results of a three-phase quality assurance (QA) programme', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CANADA, Toronto, pp. A144 - A144, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, CANADA, Toronto, 04 June 2013 - 08 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335229500117&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Tu E; Swenson LC; Land S; Pett S; Emery S; Marks K; Kelleher AD; Kaye S; Kaiser R; Schuelter E; Harrigan R, 2013, Reply to "issues on results of the external quality assessment for proviral DNA testing of HIV-1 tropism in the maraviroc switch collaborative study", http://dx.doi.org/10.1128/JCM.02207-13
